Advaxis, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 2002-01-01

Employees: 51

Market Cap: $851.8K

Website: http://www.advaxis.com

Clinical Trials

Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer, Non-Small Cell
Metastatic Squamous Cell Carcinoma
Metastatic Non-Squamous Cell Carcinoma

Interventions: Drug: ADXS-503
Drug: Pembrolizumab

First Posted Date: 2019-02-20

Last Posted Date: 2024-06-04

Lead Sponsor: Advaxis, Inc.

Target Recruit Count: 24

Registration Number: NCT03847519

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
Atlantic Health System, Carol G Simon Cancer Center, Morristown, New Jersey, United States
🇺🇸
Illinois CancerCare, P.C., Peoria, Illinois, United States

and more 6 locations

A Study of ADXS-NEO Expressing Personalized Tumor Antigens

Phase 1

Terminated

Conditions: Head and Neck Cancer Metastatic
Urothelial Carcinoma
Metastatic Melanoma
Metastatic Non-Small Cell Lung Cancer
Colon Cancer Metastatic

Interventions: Biological: ADXS-NEO
Biological: Pembrolizumab

First Posted Date: 2017-08-29

Last Posted Date: 2023-02-24

Lead Sponsor: Advaxis, Inc.

Target Recruit Count: 13

Registration Number: NCT03265080

Locations: 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Atlantic Health System, Morristown, New Jersey, United States

and more 2 locations

Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer

Phase 3

Terminated

Conditions: High Risk Cervical Cancer
Advanced Cervical Cancer

Interventions: Drug: Placebo
Drug: ADXS11-001

First Posted Date: 2016-08-03

Last Posted Date: 2023-03-14

Lead Sponsor: Advaxis, Inc.

Target Recruit Count: 110

Registration Number: NCT02853604

Locations: 🇺🇦
Site, Zaporizhzhya, Ukraine
🇨🇱
SITE, Santiago de Chile, Region Metropolitana, Chile

A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy

Phase 2

Withdrawn

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: ADXS11-001
Drug: Pemetrexed

First Posted Date: 2015-08-25

Last Posted Date: 2023-12-19

Lead Sponsor: Advaxis, Inc.

Registration Number: NCT02531854

A Phase 2 Study of Axalimogene Filolisbac (ADXS11-001) in Participants With Carcinoma of the Anorectal Canal

Phase 2

Completed

Conditions: Anal Cancer
Rectal Cancer

Interventions: Drug: Axalimogene filolisbac

First Posted Date: 2015-03-26

Last Posted Date: 2023-03-20

Lead Sponsor: Advaxis, Inc.

Target Recruit Count: 36

Registration Number: NCT02399813

Locations: 🇺🇸
Indiana University, Indianapolis, Indiana, United States
🇺🇸
Fox Chase, Philadelphia, Pennsylvania, United States

Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors

Phase 1

Completed

Conditions: HER2 Expressing Solid Tumors

Interventions: Drug: ADXS31-164

First Posted Date: 2015-03-12

Last Posted Date: 2020-07-16

Lead Sponsor: Advaxis, Inc.

Target Recruit Count: 12

Registration Number: NCT02386501

Locations: 🇺🇸
Site, Philadelphia, Pennsylvania, United States
🇺🇸
Not Yet Recruiting, Los Angeles, California, United States

ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Phase 1

Completed

Conditions: Prostate Cancer
Cancer

Interventions: Drug: ADXS31-142
Drug: Pembrolizumab

First Posted Date: 2014-12-25

Last Posted Date: 2024-04-02

Lead Sponsor: Advaxis, Inc.

Target Recruit Count: 50

Registration Number: NCT02325557

Locations: 🇺🇸
Recruiting, Providence, Rhode Island, United States
🇺🇸
Recrutiing, Philadelphia, Pennsylvania, United States
🇺🇸
University of Colorado Health Sciences Center (UCHSC), Aurora, Colorado, United States

and more 1 locations

A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer

Phase 1

Terminated

Conditions: Head and Neck Cancer
Cervical Cancer
Cancer

Interventions: Drug: ADXS11-001
Drug: MEDI4736

First Posted Date: 2014-11-14

Last Posted Date: 2023-03-20

Lead Sponsor: Advaxis, Inc.

Target Recruit Count: 75

Registration Number: NCT02291055

Locations: 🇺🇸
Site, Milwaukee, Wisconsin, United States

Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer

Phase 1

Completed

Conditions: Cervical Squamous Cell Carcinoma
Metastatic/Recurrent Cervical Cancer
Stage IVA Cervical Cancer
Cervical Adenosquamous Cell Carcinoma
Cervical Small Cell Carcinoma
Stage IVB Cervical Cancer
Effects of Immunotherapy
Cervical Adenocarcinoma
Stage III Cervical Cancer

Interventions: Biological: Axalimogene filolisbac

First Posted Date: 2014-06-16

Last Posted Date: 2024-05-20

Lead Sponsor: Advaxis, Inc.

Target Recruit Count: 12

Registration Number: NCT02164461

An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+

Phase 2

Terminated

Conditions: Cervical Intraepithelial Neoplasia

Interventions: Biological: ADXS11-001 (Lm-LLO-E7)
Drug: Placebo Control

First Posted Date: 2010-05-04

Last Posted Date: 2016-07-27

Lead Sponsor: Advaxis, Inc.

Target Recruit Count: 81

Registration Number: NCT01116245

Locations: 🇺🇸
Center for Women, Chicago, Illinois, United States
🇺🇸
Indiana University Dept. of OB/GYN Oncology, Indianapolis, Indiana, United States
🇺🇸
InVisions Consultants, LLC- c/o Institute for Women's Health, San Antonio, Texas, United States

and more 12 locations

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy